由于第二季度财报发布后持续低迷，DexCom下跌6%

2025-08-26 02:20

DexCom (NASDAQ:DXCM) is down ~6% in Monday trading, continuing a downward trend that began in late July following the release of its Q2 financial results.
While there doesn't appear to be a clear catalyst for today's decline, DexCom was trading above $89 per share just before the July 30 earnings release. On Monday, the price dropped to as low as $77.10 per share.
While DexCom's Q2 results beat on both lines and it raised its 2025 revenue guidance, the stock fell after the closing bell on July 30.
The maker of continuous glucose monitors did report that its non-GAAP gross margin fell to 60.1% from 63.5% in the year-ago period.
A look at insider transactions finds that over the last six months, there have been net share purchases (accounting for shares sold) of ~316K shares.

More on DexCom